+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030- Product Image
Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030- Product Image
Sale

Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968814
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Migraine Drugs Market grew from USD 4.74 billion in 2023 to USD 5.48 billion in 2024. It is expected to continue growing at a CAGR of 15.83%, reaching USD 13.26 billion by 2030.

The scope and definition of migraine drugs encompass pharmaceutical products specifically designed to treat and manage migraine headaches, which include both acute treatment medications and preventive medications. The necessity of migraine drugs is imperative as migraines significantly impact quality of life and productivity. These drugs are applied across various demographics, with end-users including hospitals, clinics, and homecare settings. The migraine drug market benefits from key growth factors such as an increasing prevalence of migraine cases, rising awareness about treatment options, and advancements in pharmaceutical development. The introduction of novel drug classes, such as CGRP inhibitors, reflects significant potential opportunities. Companies can capitalize on these by investing in R&D for new compounds, exploring untapped markets in developing regions, and leveraging strategic partnerships for distribution. Nonetheless, the market faces limitations such as the high cost of newly launched drugs, stringent regulatory approvals, and potential side effects that may hinder patient adoption. As a challenging factor, intense competition among existing market players can restrain pricing strategies. Innovative areas for research include exploring personalized medicine approaches, leveraging bioscience to understand genetic predispositions to migraines, and developing more effective drug delivery systems like nasal sprays or injections for quicker relief. The nature of the market is dynamic and competitive, with ongoing innovations in biologics and a trend towards more preventive treatment regimens. To successfully navigate this market, businesses should emphasize patient-centric solutions and affordability, focus on collaborations that enhance their research pipeline, and enhance their market outreach through digital platforms to educate and engage consumers effectively. This strategic approach will help companies in not only addressing the current limitations but also harnessing new opportunities for sustainable growth in the migraine drug market.

Understanding Market Dynamics in the Migraine Drugs Market

The Migraine Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing incidence of migraines and launch of new drugs
    • Rise in female population and increase in cigarette consumption
    • Advancements in healthcare facilities such as electrical nerve stimulation devices
  • Market Restraints
    • Side effects associated with migraine drugs
  • Market Opportunities
    • Supportive reimbursement policies for migraine medications
    • Increased programmes of collaboration and partnership in the pharmaceutical sector
  • Market Challenges
    • Availability of alternative therapies and regulatory challenges

Exploring Porter’s Five Forces for the Migraine Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Migraine Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Migraine Drugs Market

External macro-environmental factors deeply influence the performance of the Migraine Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Migraine Drugs Market

The Migraine Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Migraine Drugs Market

The Migraine Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Migraine Drugs Market

The Migraine Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Migraine Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aegis Therapeutics, LLC, Alder Biopharmaceuticals, Inc., Allergan Inc. by AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Biohaven, Ltd, Eisai Co., Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Migraine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutic Class
    • Anti-Nausea Drug
      • Chlorpromazine
      • Metoclopramide
      • Prochlorperazine
    • Blood Pressure Lowering Medication
      • Beta-Blocker
      • Calcium Channel Blocker
    • Ergots
      • Dihydroergotamines
      • Ergotamine
      • Lasmiditan
    • Opioid Medication
      • OxyContin
      • Percocet
      • Vicodin
    • Pain Reliever
      • Aspirin
      • Ibuprofen
    • Triptans
      • Rizatriptan
      • Sumatriptan
  • Treatment Type
    • Abortive
    • Preventive
  • Route of Administration
    • Injectable
    • Nasal Spray
    • Oral
  • Distribution
    • Hospitals Based Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Migraine Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of migraines and launch of new drugs
5.1.1.2. Rise in female population and increase in cigarette consumption
5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
5.1.2. Restraints
5.1.2.1. Side effects associated with migraine drugs
5.1.3. Opportunities
5.1.3.1. Supportive reimbursement policies for migraine medications
5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
5.1.4. Challenges
5.1.4.1. Availability of alternative therapies and regulatory challenges
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Migraine Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Anti-Nausea Drug
6.3.1. Chlorpromazine
6.3.2. Metoclopramide
6.3.3. Prochlorperazine
6.3. Blood Pressure Lowering Medication
6.4.1. Beta-Blocker
6.4.2. Calcium Channel Blocker
6.4. Ergots
6.5.1. Dihydroergotamines
6.5.2. Ergotamine
6.5.3. Lasmiditan
6.5. Opioid Medication
6.6.1. OxyContin
6.6.2. Percocet
6.6.3. Vicodin
6.6. Pain Reliever
6.7.1. Aspirin
6.7.2. Ibuprofen
6.7. Triptans
6.8.1. Rizatriptan
6.8.2. Sumatriptan
7. Migraine Drugs Market, by Treatment Type
7.1. Introduction
7.2. Abortive
7.3. Preventive
8. Migraine Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal Spray
8.4. Oral
9. Migraine Drugs Market, by Distribution
9.1. Introduction
9.2. Hospitals Based Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Migraine Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Migraine Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Migraine Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Aegis Therapeutics, LLC
14.1.3. Alder Biopharmaceuticals, Inc.
14.1.4. Allergan Inc. by AbbVie Inc.
14.1.5. Amgen, Inc.
14.1.6. AstraZeneca Plc
14.1.7. Biohaven, Ltd
14.1.8. Eisai Co., Ltd.
14.1.9. Eli Lilly and Company
14.1.10. Endo International Plc
14.1.11. GlaxoSmithKline Plc
14.1.12. H. Lundbeck A/S
14.1.13. Johnson & Johnson Services, Inc.
14.1.14. Merck & Co. Inc.
14.1.15. Pfizer Inc.
14.1.16. Sanofi SA
14.1.17. Teva Pharmaceuticals Industries Ltd
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MIGRAINE DRUGS MARKET DYNAMICS
FIGURE 7. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 8. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 10. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 14. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 6. MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 8. MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 13. MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 17. MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 22. MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 27. MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 31. MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 41. MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 75. CANADA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. CANADA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 77. CANADA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 79. CANADA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 81. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 82. CANADA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 87. MEXICO MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. CHINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. CHINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 129. CHINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 130. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 131. CHINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 132. CHINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 133. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 134. CHINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. CHINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 137. INDIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 138. INDIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 139. INDIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 140. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 141. INDIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 142. INDIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 143. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 144. INDIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. INDIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 157. JAPAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 158. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 159. JAPAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 160. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 162. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 163. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 217. THAILAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 218. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 219. THAILAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 220. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 222. THAILAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 223. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. THAILAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 250. DENMARK MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 253. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 254. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 258. EGYPT MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 260. EGYPT MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 261. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 263. EGYPT MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 264. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. EGYPT MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 268. FINLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 269. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 270. FINLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 271. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 273. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 274. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 278. FRANCE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 279. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 280. FRANCE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 281. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 283. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 284. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 288. GERMANY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 289. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 290. GERMANY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 291. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 293. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 294. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 308. ITALY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 309. ITALY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 310. ITALY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 311. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 312. ITALY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 313. ITALY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 314. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 315. ITALY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 316. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 338. NORWAY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 339. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 340. NORWAY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 341. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 342. NORWAY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 343. NORWAY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 344. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 345. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 346. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. NORWAY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 348. POLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 349. POLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
TABLE 350. POLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
TABLE 351. POLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
TABLE 352. POLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
TABLE 353. POLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
TABLE 354. POLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
TABLE 355. POLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 356. POLAND MIGRAINE DRUGS MARKET SIZE,

Companies Mentioned

The leading players in the Migraine Drugs Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Aegis Therapeutics, LLC
  • Alder Biopharmaceuticals, Inc.
  • Allergan Inc. by AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Biohaven, Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.26 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 159 Pages
  • Global
From
Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 135 Pages
  • Global
From
Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Migraine Drugs Global Market Report 2024 - Product Image

Migraine Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From

About the Migraine Drug Market

The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists. Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.